Yusuke Nakamura to Prostatic Neoplasms
This is a "connection" page, showing publications Yusuke Nakamura has written about Prostatic Neoplasms.
Connection Strength
1.238
-
Prostate cancer genomics, biology, and risk assessment through genome-wide association studies. Cancer Sci. 2012 Apr; 103(4):607-13.
Score: 0.188
-
PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Cancer Res. 2005 Jun 01; 65(11):4578-86.
Score: 0.118
-
Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res. 2004 Sep 01; 64(17):5963-72.
Score: 0.112
-
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6.
Score: 0.109
-
Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project. J Epidemiol. 2017 Mar; 27(3S):S65-S70.
Score: 0.067
-
Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide. J Proteome Res. 2013 Oct 04; 12(10):4497-506.
Score: 0.053
-
Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese. PLoS One. 2012; 7(10):e46454.
Score: 0.049
-
Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiol Biomarkers Prev. 2012 Nov; 21(11):2048-58.
Score: 0.049
-
Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet. 2012 Feb 26; 44(4):426-9, S1.
Score: 0.047
-
IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility. Hum Mol Genet. 2012 May 01; 21(9):2076-85.
Score: 0.047
-
Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011 Jan; 102(1):245-52.
Score: 0.043
-
A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum Mol Genet. 2010 Nov 01; 19(21):4265-72.
Score: 0.042
-
Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010 Sep; 42(9):751-4.
Score: 0.042
-
5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. Cancer Sci. 2010 Aug; 101(8):1897-904.
Score: 0.042
-
Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res. 2009 Oct 15; 69(20):8133-40.
Score: 0.040
-
Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. Cancer Sci. 2009 Nov; 100(11):2109-14.
Score: 0.039
-
Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci. 2009 May; 100(5):914-9.
Score: 0.038
-
Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008 Jan; 99(1):81-6.
Score: 0.035
-
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 2007 Jun 01; 67(11):5117-25.
Score: 0.034
-
Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression. Clin Cancer Res. 2006 May 01; 12(9):2767-73.
Score: 0.032
-
CLCA2 as a p53-inducible senescence mediator. Neoplasia. 2012 Feb; 14(2):141-9.
Score: 0.012